Iovance Biotherapeutics (IOVA) Misses Q2 EPS by 5c, reiterates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Unity Software stock soars 22% on strong Q3 beat, robust guidance
Tweet
Share
E-mailGet Alerts IOVA Hot Sheet
Join SI Premium – FREE
Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.33), $0.05 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $60 million versus the consensus estimate of $67.1 million.
GUIDANCE:
Iovance Biotherapeutics sees FY2025 revenue of $250-300 million, versus the consensus of $287.1 million.
For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
- Sabre (SABR) Tops Q3 EPS by 8c
- MACOM Technology Solutions (MTSI) Tops Q4 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
